関連する実験動画

Updated: Nov 29, 2025

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure
09:38

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure

Published on: August 11, 2017

9.0K

トランスまたはシスダイマーインターフェース変異によるIDH阻害に対する獲得抵抗

Andrew M Intlekofer1,2,3,4, Alan H Shih1,2,4,5, Bo Wang1,2,6

  • 1Human Oncology & Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA.

Nature
|June 29, 2018
PubMed
まとめ

イソシトラ脱水素酵素2 (IDH2) の体内の変異が急性骨髄性白血病 (AML) を誘発する. 新しいIDH2変異が発生し,エナシデニブのような標的治療に対する耐性を引き起こし,2- ヒドロキシグルタレート (2HG) の生成を可能にします.

さらに関連する動画

Implementation of In Vitro Drug Resistance Assays: Maximizing the Potential for Uncovering Clinically Relevant Resistance Mechanisms08:46

Implementation of In Vitro Drug Resistance Assays: Maximizing the Potential for Uncovering Clinically Relevant Resistance Mechanisms

Published on: December 9, 2015

10.9K
A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors12:40

A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors

Published on: December 7, 2014

15.1K

関連する概念動画

Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.5K